GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
by FB. we really should be higher than this, the RNS was late in the day - doesnt help at all. The name of the company doesnt represent imaging at all. Its RNS could be getting missed by aim punters as this is main market. Just going to have to hold. If wider marker picks up on this can easily get to 20p plus. in my opinion. No advice intended.
Expected June but these guys have met deadlines way before so im looking at it getting approved within next few weeks so a rise in anticipation of approval is expected. Also waiting on sales from Asia and Europe. Expecting orders from South Korea in particular, Jacob Woo seems to be a connected guy with bags of industry experience. Other partnership deals with GE for example like FDBK did could be game changing.
Absolutely Francobrett. I agree, the acquisition of IB was a bargain in my opinion, TB stated that IB has sales and in the current market space its a real coup especially with it having FDA approval. It adds more expertise to the team also. All BoD are substantial shareholders so their interests are aligned. TB also said the guys are working 7 days a week to progress this company so we can be rest assured that the only way from here is most definitely up.
and only 72m shares Wisha
The more I think about it the better the acquisition of Imaging Biometrics appears. It derisks StoneChecker with the brain tumour software so FBDU is no longer a one trick pony while also providing a quick route to FDA approval for the enormous US market. Once up and running I'm sure there will be further acquisitions in the bid to come a significant participant in the fast developing field of imaging diagnostics and medical AI. IMO
4.01/4.09 looking good. Bit of buying pressure and its 4.5p on the ask. Bid upto 4p mm's want shares. When volume returns will be difficult to get a live price.
On a few buys.. imagine what will happen when volume returns. Best time to buy when its quiet.
Something brewing all of a sudden....
'The acquisition of IB represents the first step in the execution of our vision to become a significant participant in the field of medical imaging diagnostics and the application of artificial intelligence in medical imaging.' TB If you believe the adoption of medical AI is the future then FBDU are well positioned to take advantage. Beginning of this story. Long term hold IMO
If anyone wants to read the full financials and update....? .https://www.investegate.co.uk/flying-brands-ltd--fbdu-/rns/final-results/201804301625456281M/ Event since the year end In March 2018, the Company acquired 100% of the membership interests in Imaging Biometrics, LLC ("IB") (the "Acquisition"). The consideration comprises cash of $68,134 and 11,000,000 ordinary shares in Flying Brands at �0.04 per share ("Shares"), with an option for Flying Brands to pay a cash equivalent rather than issuing Shares. An initial tranche of 4,800,000 Shares in Flying Brands was issued to the shareholders of IB immediately (the "Initial Tranche") and it is intended that the remaining 6,200,000 Shares will be issued before 30 September 2018. The consideration must be satisfied in full on or before 30 September 2018. In addition, Flying Brands is paying an additional $75,000 to settle certain of IB's debt obligations. IB, a privately held Wisconsin-based company established in January 2007, is advancing the field of medical imaging by specialising in the design and manufacture of advanced visualisation software solutions using quantitative imaging endpoints/biomarkers. IB are specialists in research, manufacturing and clinical evaluation of software products in radiology and have successfully developed products from the discovery phase through to full FDA regulatory approval. In the USA, IB have commercialised the premier perfusion software solution IB Neuro� which is able to provide biologic information about tumours not available with current medical imaging platforms. Over the past decade, they have installed IB Neuro and other IB-branded software in numerous sites where it has been integrated into routine clinical practice. For example, IB Rad Tech� streamlines a perfusion MRI ("pMRI") based method called Fractional Tumour Burden ("FTB"). Based on recent published data, the underlying technology in IB's solutions has demonstrated the ability of FTB to more accurately distinguish tumour from Post-Treatment Radiation Effect over conventional methods and is now gaining trust by clinicians for the evaluation and monitoring of brain tumour patients.
Why would anyone sell at current price? unless desperate ofcourse. The shares are trading at a lower price than before Stonechecker had FDA approval and before acquisition of IB. £2.7mcap and distribution agreements signed with S. Korea with more discussions with India and China. A potential buyer in Germany. The largest market is the USA where IB has FDA approval and Stonechecker will get approval within next 8weeks max. With such a small Freefloat and low mcap this is primed for a rise into double digits. I will load up more if it drops even slightly. DYOR.
None so far. But to be honest I hope they do sell as it would be nice to average down. Sales to India, China and the US and the map 2.7m?
Seems a good rns but the problem Is it seems like we need to wait till q3 really. Any thoughts ?
- Create a new company to support product maintenance and development, regulatory clearances, commercialisation including international sales channel management - Recruit a high quality hands-on Chief Operations Officer to further refine the business plan, drive commercial sales and oversee recruitment. In particular, the COO will be responsible for increasing sales of Imaging Biometrics' products in the US and launching these products in India, China and Europe (Q3 2018) - Recruit one administrative support worker and marketing staff (Q4 2018) - Obtain FDA clearance for StoneChecker Software (Q2/Q3 2018) and then market StoneChecker Software commercially in the US, India and China (completion: Q3/Q4 2018) - Appoint a second person to the Business Development team to be responsible for the US and other North American markets. - Design and manufacture a commercial version of the cloud-based interface for StoneChecker Software (completion: Q3 2018) - Commercial sales of StoneChecker Software in the UK (completion: Q4 2018) - Create a network of distributors worldwide (Ongoing) - Setting up reference centres across important research centres in association with key opinion leaders; - Setting up a clinical case registry to collect anonymised case data, to be used to develop Artificially Intelligent products at a future date; - Supporting the conduct of investigator led studies at renowned academic institutions globally; - Setting up cloud services platform and innovative licensing models (e.g. subscription-model, pay per use etc and having the necessary infrastructure and payment portal, tracking customer usage) for the Products; - Developing next generation/improved versions of StoneChecker Software and Imaging Biometrics' products; - Applying for and maintaining regulatory clearances with the appropriate national competent authorities.
CompanyEPIC/TIDMSEDOL/ISIN Share Tweet Print RSS Flying Brands Ltd (FBDU) Flying Brands Ltd Final Results RNS Number : 6281M Flying Brands Limited 30 April 2018 Flying Brands Limited ("Flying Brands" or the "Company") Final Audited Results Flying Brands announces today its audited financial results for the year ended 31 December 2017. For further information, please contact: Flying Brands Limited 0207 469 0930 Trevor Brown Peterhouse Corporate Finance Limited 0207 220 9797 Lucy Williams/ Heena Karani Chief Executive's Statement It is with pleasure that I present the annual financial statements to shareholders for the year ended 31 December 2017. This year has been one of transition and we have made considerable progress in implementing our plans: � In June 2017, we raised �550,000, completed the acquisition of Stone Checker Software� Ltd ("Stone Checker") and the Company was readmitted to trading on the standard segment of the Main Market; � In October 2017, we announced that the prototype testing and evaluation by the StoneChecker team of its StoneChecker� Kidney Stone analysis software ("StoneChecker Software") had been successfully completed; and � In December 2017, StoneChecker announced that it had affixed a CE mark to 'StoneChecker', thereby confirming that the software now meets the requirements of the Medical Device Directive (MDD-93/42EEC) and satisfies the quality, safety and performance standards for medical devices in the European Union (EU), paving the way for the commercial application of StoneChecker Software. Outlook Post the year-end, the Company announced that Stone Checker signed an exclusive marketing and distribution agreement with Korea Computer Motion ISG, for sales and distribution of its StoneChecker Software. In addition, the Company acquired Imaging Biometrics ("IB") a Wisconsin-based company advancing the field of medical imaging by specialising in the design and manufacture of advanced visualisation software solutions using quantitative imaging endpoints/biomarkers. IB are specialists in research, manufacturing and clinical evaluation of software products in radiology and have successfully developed products from the discovery phase through to full FDA regulatory approval. The acquisition of IB represents the first step in the execution of our vision to become a significant participant in the field of medical imaging diagnostics and the application of artificial intelligence in medical imaging. We look forward to the future with confidence and excitement. Trevor Brown Chief Executive Officer 27 April 2018 Principal activities The principal activity in the year ended 31 December 2017 is the provision of convenient, cost-effective and clinical treatment to patients based o
The Board of Flying Brands consider that by utilising the StoneChecker software, a significant portion of the estimated US $50million spent on conducting failed lithotripsies in South Korea each year, could be saved. That is a MASSIVE amount of money spent on FAILED lithotripsies, and its ONLY S. Korea (population 50M) imagine the savings worldwide!! no wonder the BoD are excited. Don't forget Stonechechecker is one part of the portfolio. We also own Imaging Biometrics - Potential is huge. Any news of sales and its fireworks here.
Just watched Trevor Brown's latest interview with Andrew. He seems extremely excited to say the least, similarly Nick Stevens seems in the exact same mood whenever he conducts interviews also. All the BoD are substantial shareholders which i really like here. £2.7m mcap with two major Catalysts due anyday - FDA approval, worldwide sales. I can easily see this £10m mcap in the near future with the tiny free float. DYOR
New investors video http://www.proactiveinvestors.co.uk/companies/stocktube/8898/flying-brands-on-the-front-line-of-the-medical-imaging-revolution-8898.html Flying Brands on the front line of the medical imaging revolution 19 Mar 2018 Trevor Brown, executive director at Flying Brands Limited (LON:FBDU), chats with Proactive's Andrew Scott about the strategy and longer term plans for the company. Brown says all operational personnel are substantial shareholders. ''I think that's a very important part of the perspective that the team has in terms of what they're doing''. ''From Flying Brands point of view I see it a bit like building a premier league team ... we have luxury of being able to look around the world to see where the talent is, to talk to people and see whether they will join us - Imaging Biometrics being the most recent example''.
check out previous articles- news http://www.proactiveinvestors.co.uk/LON:FBDU/Flying-Brands-Ltd/ http://www.proactiveinvestors.co.uk/companies/rns/3867/LSE20180411070002_13599513
I recall our ceo mentioning sales in India in his last interview. He said the market there was quite fragmented. I still expect the Germany news first as per his interview. Surely UK deals being negotiated as well.
Yes draft, ...but can't find anything to update with....like your posts.....I don't want to be 'tagged' a ramper...lol http://pumpedordumped.com/rampchecker/rampchecktopramper.php
feddback rns this morning. FBDU will also do deal with GE Healthcare so obvious
...is soon to be delivered....it’s a coiled spring but blimey it’s taking its time to release....was hoping first sales no matter how small may have been released by now through one of the agreements...
Because people don't post frequently doesn't mean investors have done a runner. Been here years and still entirely confident. I don't post if its not necessary. ATB.